Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib/Binimetinib +/- Nivolumab in Metastatic BRAF V600 Mutant Thyroid Cancer
NCT04061980Phase 2Active, not recruiting
- Start
- Oct 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib, nivolumab in differentiated thyroid cancer (DTC). Started Oct 2020; status: active, not recruiting.
02
Drugs
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT04061980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061980.